Long-term thalidomide for actinic prurigo

Australasian Journal of Dermatology

Volumn 42, Issue 4, 2001, Pages 281-283

  Yong Gee, Simon A ^a,b   Muir, James B ^a  

^a MATER HOSPITAL   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Neurotoxicity; Polymorphic light eruption

Indexed keywords

HLA DR4 ANTIGEN; THALIDOMIDE;

ADULT; ARTICLE; BODY REGIONS; CASE REPORT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; FACE; HUMAN; LIGHT EXPOSURE; MAINTENANCE THERAPY; MALE; NEUROPATHY; PHOTOSENSITIVITY DISORDER; PRURIGO; PRURITUS; RECURRENT DISEASE;

ADULT; HLA-DR4 ANTIGEN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; PHOTOSENSITIVITY DISORDERS; PRURIGO; THALIDOMIDE;

EID: 0035655627     PISSN: 00048380     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-0960.2001.00536.x     Document Type: Article

References (11)

1. Cutaneous photobiology
2. Actinic prurigo and polymorphic light eruption: Common pathogenesis and the importance of HLA-DR4/DRB1*0407
3. Actinic prurigo and HLA-DR4
4. Thalidomide in the treatment of actinic prurigo
5. Thalidomide in actinic prurigo
6. Rediscovering thalidomide. A review of its mechanism of action, side effects and potential uses
7. American experience with low-dose thalidomide therapy for severe cutaneous lupus erythematosus
8. Development of polyneuropathy during thalidomide therapy
9. Thalidomide neuropathy. A clinical, electrophysiological, and histological follow-up study
10. Thalidomide neuropathy incidence and clinico-electrophysiologic findings in 42 patients
11. Thalidomide-induced neuropathy and genetic differences in drug metabolism